[3-(2-甲基-哌啶-1-基)-丙基]-(2-硝基-苯基)-胺 | 1023699-50-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: [3-(2-甲基-哌啶-1-基)-丙基]-(2-硝基-苯基)-胺
• 英文名称: [3-(2-methyl-piperidin-1-yl)-propyl]-(2-nitro-phenyl)-amine
• 英文别名: N-[3-(2-methylpiperidin-1-yl)propyl]-2-nitroaniline
• CAS: 1023699-50-4
• 化学式: C₁₅H₂₃N₃O₂
• 分子量: 277.367
• InChiKey: JICQGBFEGLSJRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  61.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [3-(2-甲基-哌啶-1-基)-丙基]-(2-硝基-苯基)-胺 在 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以2.53 g的产率得到N-[3-(2-methyl-piperidin-1-yl)-propyl]-benzene-1,2-diamine
  参考文献：
  名称：

  Parallel synthesis of a series of potentially brain penetrant aminoalkyl benzoimidazoles

  摘要：

  Alpha7 agonists were identified via GOLD (CCDC) docking in the putative agonist binding site of an alpha7 homology model and a series of aminoalkyl benzoimidazoles was synthesised to obtain potentially brain penetrant drugs. The array was prepared starting from the reaction of ortho-fluoronitrobenzenes with a selection of diamines, followed by reduction of the nitro group to obtain a series of monoalkylated phenylene diamines. N,N'-Carbonyidiimidazole (CDI) mediated acylation, followed by a parallel automated work-up procedure, afforded the monoacylated phenylenediamines which were cyclised under acidic conditions. Parallel work-up and purification afforded the array products in good yields and purities with a robust parallel methodology which will be useful for other libraries. Screening for alpha7 activity revealed compounds with agonist activity for the receptor. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.068
• 作为产物：
  描述：

  3-(2-Methyl-piperidino)-propylamin 、 1-氟-2-硝基苯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 [3-(2-甲基-哌啶-1-基)-丙基]-(2-硝基-苯基)-胺
  参考文献：
  名称：

  Parallel synthesis of a series of potentially brain penetrant aminoalkyl benzoimidazoles

  摘要：

  Alpha7 agonists were identified via GOLD (CCDC) docking in the putative agonist binding site of an alpha7 homology model and a series of aminoalkyl benzoimidazoles was synthesised to obtain potentially brain penetrant drugs. The array was prepared starting from the reaction of ortho-fluoronitrobenzenes with a selection of diamines, followed by reduction of the nitro group to obtain a series of monoalkylated phenylene diamines. N,N'-Carbonyidiimidazole (CDI) mediated acylation, followed by a parallel automated work-up procedure, afforded the monoacylated phenylenediamines which were cyclised under acidic conditions. Parallel work-up and purification afforded the array products in good yields and purities with a robust parallel methodology which will be useful for other libraries. Screening for alpha7 activity revealed compounds with agonist activity for the receptor. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.068

文献信息

• Parallel synthesis of a series of potentially brain penetrant aminoalkyl benzoimidazoles
  作者：Iolanda Micco、Arianna Nencini、Joanna Quinn、Hendrick Bothmann、Chiara Ghiron、Alessandro Padova、Silvia Papini

  DOI：10.1016/j.bmc.2007.11.068

  日期：2008.3

  Alpha7 agonists were identified via GOLD (CCDC) docking in the putative agonist binding site of an alpha7 homology model and a series of aminoalkyl benzoimidazoles was synthesised to obtain potentially brain penetrant drugs. The array was prepared starting from the reaction of ortho-fluoronitrobenzenes with a selection of diamines, followed by reduction of the nitro group to obtain a series of monoalkylated phenylene diamines. N,N'-Carbonyidiimidazole (CDI) mediated acylation, followed by a parallel automated work-up procedure, afforded the monoacylated phenylenediamines which were cyclised under acidic conditions. Parallel work-up and purification afforded the array products in good yields and purities with a robust parallel methodology which will be useful for other libraries. Screening for alpha7 activity revealed compounds with agonist activity for the receptor. (C) 2007 Elsevier Ltd. All rights reserved.